TABLE 1

Clinical characteristics of the study participants

IGT relativesControl subjectsP
n89
Age (years)55 ± 253 ± 2NS
Weight (kg)102 ± 5106 ± 5NS
Height (cm)178 ± 3181 ± 1NS
BMI (kg/m2)31.9 ± 1.032.3 ± 1.3NS
Waist/hip ratio1.00 ± 0.011.00 ± 0.02NS
FFM (kg)67.1 ± 2.069.0 ± 3.2NS
Fasting plasma glucose (mmol/l)6.6 ± 0.25.9 ± 0.10.02
2-h plasma glucose (mmol/l)9.3 ± 0.45.5 ± 0.3<0.0001
Plasma FFA (mmol/l)0.40 ± 0.060.44 ± 0.04NS
Plasma triglyceride (mmol/l)2.2 ± 0.51.3 ± 0.2NS
Plasma cholesterol (mmol/l)5.5 ± 0.25.7 ± 0.4NS
HbA1c (%)6.0 ± 0.36.0 ± 0.1NS
Plasma C-peptide (pmol/l)
 Basal1,202 ± 195619 ± 860.0037
 IS1,066 ± 174648 ± 710.046
Plasma insulin (pmol/l)
 Basal96.1 ± 27.739.1 ± 4.8NS
 IS487.5 ± 54.2442.7 ± 24.9NS
Hepatic glucose production (mg · kg FFM–1 · min−1)
 Basal2.81 ± 0.242.38 ± 0.20NS
 ISu1.52 ± 0.412.09 ± 0.38NS
AUC10 min insulin (pmol · l–1 · min–1)2,530 ± 10321,698 ± 454NS
  • Data are means ± SE. IS, insulin-stimulated (during euglycemic clamp); ISu, insulin suppressed (during euglycemic clamp); NS, not significant.